易狐药讯 vs e准入
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
易狐药讯
Read full descriptionHide full description
【易狐药讯】是星辰启联（南京）数字技术有限责任公司旗下开发的网上药品信息交流平台。主要板块有医药招商、政策资讯、视频访谈、信息发布等多个模块；为用户提供最方便的数据查询、产品信息交流、资讯政策浏览等功能。
e准入
Read full descriptionHide full description
医药招投标人的智能工作台，精准掌控招标动态与日程 ，专为药品生产流通企业、医疗机构、政府机构打造的垂直领域工具，整合资讯+日程+分析的一站式平台。
Screenshots
Verdict
易狐药讯 and e准入 are too close to call on the numbers: across 6 compared parameters — price, update cadence, ads and in-app purchases among them — neither pulls far enough ahead to decide it. What separates them is feature set and interface, not measurable difference.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
易狐药讯 ships an update fortnightly, e准入 every 4 weeks. The most recent releases landed on October 1, 2026 and October 2, 2026 respectively.
| Parameter | 易狐药讯 | e准入 |
|---|---|---|
| Price | Free | Free |
| Update frequency | Fortnightly — better | Every 4 weeks |
| Ads | No | No |
| In-app purchases | No | No |
| Devices | iPhone, iPad, iPod — better | iPhone, iPod |
| Requires iOS | 12.0 | 12.0 |
| Further details — not scored | ||
| Size | 18 MB | 67 MB |
| Age rating | 17+ | 4+ |
| Developer | Logic Solutions Shanghai Co., Ltd. | 南京易联阳光信息技术股份有限公司 |
In-app purchases
易狐药讯
No in-app purchases
e准入
No in-app purchases
